About 60° Pharmaceuticals
Our company history and mission
60° Pharmaceuticals (60P) was founded in 2010 with a mission to realize new ways to improve and extend people’s lives by discovering, developing, and distributing new best-in-class medicines for the treatment and prevention of tropical diseases. The Company is now developing and commercializing products more broadly for infectious disease.
We apply the same passion, energy, and culture of innovation that allowed the successful approval of ARAKODA® (tafenoquine) to making a difference in the world. We are committed to finding the tools and strategies that will help us overcome some of the planet’s greatest health challenges.
Our core business is delivering infectious disease drug development and commercialization while providing an attractive ROI.
Our collaborative approach
60P has embraced an open innovation approach to reduce the time, cost, and risk needed to build a portfolio of drug discovery and development projects. We collaborate with leading research institutions to discover and develop medicines for infectious diseases.
Our intention is to become the trusted leader in changing the practice of malaria prevention and forging new weapons to combat life-threatening infectious diseases.
Headquarters: Washington, DC (USA)
Research & Development: Australia
FORWARD LOOKING STATEMENTS: This presentation includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding our expectations surrounding the potential of our product candidates, ARAKODA, and expectations regarding our pipeline, including trial design and development timelines. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: uncertainty around and costs associated with the development of ARAKODA as a potential treatment for COVID-19 and our other product candidates; dependence on management, directors and other key personnel; the impact of the COVID-19 pandemic on our business; our need for substantial additional funding; our dependence on the success of our most advanced product candidates; risks related to the regulatory approval process; risks associated with the clinical development process and reliance on interim or topline clinical trial results; risks related to healthcare laws and other legal compliance matters; risks related to potential commercialization; risks related to manufacturing and our dependence on third parties; risks relating to intellectual property; our ability to maintain effective internal control over financial reporting and the significant costs as a result of operating as a company. These important factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management’s estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change.